small molecule

YUVEZZI

BRIMONIDINE TARTRATE; CARBACHOL

Loss of exclusivityNovember 2042latest FDA-listed patent expiry

CompanyVisus Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	YUVEZZI
Active ingredient	BRIMONIDINE TARTRATE; CARBACHOL
Strength	0.1%;2.75%
Dosage form	SOLUTION/DROPS
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	January 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
12268662	November 2042	product
8455494	May 2030	use U-4420

Regulatory exclusivity

Code	Expires
NP	January 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.